Pharming announces the successful completion of patient enrolment in the pivotal Phase II/III triple-blind, randomized, placebo-controlled study of leniolisib for the treatment of activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS).
With completion of enrolment, we move one step closer to making this medicine available for APDS patients around the world.
- Anurag Relan - Chief Medical OfficerAttachments
- Original document
- Permalink
Disclaimer
Pharming Group NV published this content on 23 June 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 23 June 2021 07:32:05 UTC.